Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SHBG | P04278 | 4/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.45 |
| ▸ | AR | P10275 | 1/20 | 0.45 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.41 |
| ▸ | GPBAR1 | Q8TDU6 | 2/20 | 0.41 |
| ▸ | SERPINA6 | P08185 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4231498 | 0.90 | SHBG (0.38) | SHBGESR1ARESR2LMNA | |
| SCHEMBL3856204 | 0.86 | SHBG (0.41) | SHBGESR1ARESR2LMNA | |
| SCHEMBL6349934 | 0.75 | CYP19A1 (0.49) | SHBGLMNAGPBAR1SERPINA6CYP1A2 | |
| SCHEMBL6262886 | 0.75 | CYP19A1 (0.49) | SHBGLMNAGPBAR1SERPINA6CYP1A2 | |
| SCHEMBL6262894 | 0.75 | CYP19A1 (0.49) | SHBGLMNAGPBAR1SERPINA6CYP1A2 | |
| SCHEMBL15045293 | 0.73 | GPBAR1 (0.46) | LMNAGPBAR1 | |
| SCHEMBL9010657 | 0.73 | UGT2B7 (0.32) | — | |
| SCHEMBL15045297 | 0.73 | GABRP (0.46) | LMNACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL9010649 | 0.73 | GABRP (0.46) | LMNACYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL12432300 | 0.73 | ESR1 (0.41) | SHBGESR1ARESR2LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170114013-A1 | LOW CALCEMIC, HIGHLY ANTIPROLIFERATIVE, ANALOGS OF CALCITRIOL | NATIONAL INSTITUTES OF HEALTH - DIRECTOR DEITR | 2017-04-27 | — | — | US | disclosed |
| US-9481646-B2 | Low calcemic, highly antiproliferative, analogs of calcitriol | THE JOHNS HOPKINS UNIVERSITY (US) | 2016-11-01 | — | — | US | disclosed |
| US-7893043-B2 | 2-methylene-(17Z)-17(20)-dehydro-19,21-dinor-1 alpha ,25-dihydroxyvitamin D3; exhibits relatively high transcription activity as well as pronounced activity in arresting proliferation of undifferentiated cells and inducing their differentiation to the monocyte thus evidencing use as an anti-cancer agents | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2011-02-22 | — | — | US | disclosed |
| US-20100137262-A1 | Low Calcemic, Highly Antiproliferative, Analogs of Calcitriol | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2010-06-03 | — | — | US | disclosed |
| US-20100009942-A1 | 2-Methylene-(17Z)-17(20)-Dehydro-19,21-Dinor-Vitamin D Analogs | WISCONSIN ALUMNI RESEARCH FOUNDATION | 2010-01-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170114013-A1 | LOW CALCEMIC, HIGHLY ANTIPROLIFERATIVE, ANALOGS OF CALCITRIOL | VDR, CYP24A1, CYP27B1 | SHBG 1317/4885ESR1 1703/4885AR 2656/4885 |
| US-20100137262-A1 | Low Calcemic, Highly Antiproliferative, Analogs of Calcitriol | VDR, CYP24A1, CYP27B1 | SHBG 1317/4885ESR1 1703/4885AR 2656/4885 |
| US-20100009942-A1 | 2-Methylene-(17Z)-17(20)-Dehydro-19,21-Dinor-Vitamin D Analogs | CYP24A1, CYP27B1, VDR | SHBG 477/4885ESR1 3573/4885AR 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.